Nantahala Capital Management LLC Invests $14.68 Million in Apyx Medical Corporation $APYX

Nantahala Capital Management LLC purchased a new position in Apyx Medical Corporation (NASDAQ:APYX) in the second quarter, Holdings Channel reports. The fund purchased 3,270,248 shares of the company’s stock, valued at approximately $14,683,414. Nantahala Capital Management LLC owned 0.08% of Apyx Medical as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Apyx Medical by 3.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after buying an additional 53,175 shares during the last quarter. AIGH Capital Management LLC bought a new position in Apyx Medical in the second quarter worth about $5,066,000. Silverberg Bernstein Capital Management LLC lifted its holdings in Apyx Medical by 0.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock worth $3,842,000 after acquiring an additional 8,067 shares during the last quarter. Sei Investments Co. boosted its stake in Apyx Medical by 298.6% in the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after acquiring an additional 448,174 shares during the period. Finally, BlackRock Inc. acquired a new position in Apyx Medical in the second quarter valued at approximately $2,519,000. 55.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. HC Wainwright started coverage on Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.60.

Apyx Medical Stock Performance

APYX stock opened at $3.08 on Friday. The company has a 50-day simple moving average of $3.87 and a 200 day simple moving average of $3.84. The company has a market capitalization of $129.73 million, a P/E ratio of -15.40 and a beta of 1.39. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19. Apyx Medical Corporation has a fifty-two week low of $1.70 and a fifty-two week high of $5.08.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. The firm had revenue of $13.88 million for the quarter, compared to analysts’ expectations of $13.18 million. Sell-side analysts predict that Apyx Medical Corporation will post -0.25 earnings per share for the current fiscal year.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.